Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.

Thumbnail
Name:
Anti-anagiogenic-therapy.pdf
Size:
127.6Kb
Format:
PDF
Download
Authors
Korpanty, Grzegorz
Smyth, Elizabeth
Sullivan, Laura A
Brekken, Rolf A
Carney, Desmond N
Affiliation
Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. greg.korpanty@gmail.com
Issue Date
2010-01
MeSH
Angiogenesis Inhibitors
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
Humans
Lung Neoplasms
Neovascularization, Pathologic
Piperidines
Quinazolines
Receptor, Epidermal Growth Factor

Metadata
Show full item record
Citation
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. 2010, 235 (1):3-9 Exp. Biol. Med. (Maywood)
Journal
Experimental biology and medicine (Maywood, N.J.)
URI
http://hdl.handle.net/10147/99108
DOI
10.1258/ebm.2009.009191
PubMed ID
20404013
Abstract
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
Item Type
Preprint
Language
en
ISSN
1535-3699
Collections